Effects of Golimumab and Ustekinumab on Circulating Dendritic Cell Migratory Capacity in Inflammatory Bowel Disease
Open Access
- 18 October 2023
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 11 (10) , 2831
Abstract
Inflammatory bowel disease (IBD) is a chronic condition which includes ulcerative colitis (UC) and Crohn’s disease (CD), the origins of which are not yet fully understood. Both conditions involve an exacerbated immune response in the intestinal tract, leading to tissue inflammation. Dendritic cells (DCs) are antigen-presenting cells crucial for maintaining tolerance in the gastrointestinal mucosa. Previous research has indicated that DC recruitment to the intestinal mucosa is more pronounced in individuals with IBD, but the specific mechanisms governing this migration remain unclear. This study aimed to assess the expression of various homing markers and the migratory abilities of circulating DC subsets in response to intestinal chemotactic signals. Additionally, this study examined how golimumab and ustekinumab impact these characteristics in individuals with IBD compared to healthy controls. The findings revealed that a particular subset of DCs known as type 2 conventional DCs (cDC2) displayed a more pronounced migratory profile compared to other DC subsets. Furthermore, the study observed that golimumab and ustekinumab had varying effects on the migratory profile of cDC1 in individuals with CD and UC. While CCL2 did not exert a chemoattractant effect on DC subsets in this patient cohort, treatment with golimumab and ustekinumab enhanced their migratory capacity towards CCL2 and CCL25 while reducing their migration towards MadCam1. In conclusion, this study highlights that cDC2 exhibits a heightened migratory profile towards the gastrointestinal mucosa compared to other DC subsets. This finding could be explored further for the development of new diagnostic biomarkers or the identification of potential immunomodulatory targets in the context of IBD.Keywords
Funding Information
- Instituto de Salud Carlos III (CD21/00014)
- Janssen (CD21/00014)
- Merck Sharp & Dohme Corp. (CD21/00014)
This publication has 32 references indexed in Scilit:
- Chemokine (C-C Motif) Receptor 2 Mediates Dendritic Cell Recruitment to the Human Colon but Is Not Responsible for Differences Observed in Dendritic Cell Subsets, Phenotype, and Function Between the Proximal and Distal ColonCellular and Molecular Gastroenterology and Hepatology, 2016
- Expression of CCL20 and Its Corresponding Receptor CCR6 Is Enhanced in Active Inflammatory Bowel Disease, and TLR3 Mediates CCL20 Expression in Colonic Epithelial CellsPLOS ONE, 2015
- Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's diseaseAlimentary Pharmacology & Therapeutics, 2015
- Differential accumulation and function of proinflammatory 6-sulfo LacNAc dendritic cells in lymph node and colon of Crohn’s versus ulcerative colitis patientsJournal of Leukocyte Biology, 2015
- Compartment-specific immunity in the human gut: properties and functions of dendritic cells in the colon versus the ileumGut, 2015
- Localization of dendritic cells in the gut epithelium requires MAdCAM-1Clinical Immunology, 2015
- Epidermal Th22 and Tc17 Cells Form a Localized Disease Memory in Clinically Healed PsoriasisThe Journal of Immunology, 2014
- Homing marker expression on circulating dendritic cells correlates with different phenotypes of Crohn's diseaseJournal of Crohn's and Colitis, 2013
- Pathophysiology of Inflammatory Bowel Disease: An OverviewSurgical Clinics of North America, 2007
- Immunobiology of Dendritic CellsAnnual Review of Immunology, 2000